Cancer Immunotherapy in China: Obtaining a Written Follow-Up Plan

Why a written plan matters more than a discharge summary

Immunotherapy helps the immune system act against cancer, and whether it is appropriate depends on the cancer and individual assessment. That assessment is only the start. The harder question for an overseas patient is what happens after the treatment phase in China ends and monitoring moves partly or wholly to another clinician.

A discharge summary describes what happened. A follow-up plan describes what should happen next, who owns each task, and what triggers a change. Those are different documents. If you leave China with only a summary, your home clinician may know the drug and the last dose but not the intended monitoring interval, the specific tests the Chinese team wants, or how to reach them with an abnormal result.

The plan also protects continuity if you need to return to China. A written record of the original assessment, the treatment given, and the intended review points makes a later conversation about continuing care far more concrete than memory or a phone call.

Ask for the plan in writing before discharge, not after you arrive home. Once you have left, obtaining signatures, clarifications, and translated documents becomes slower and more uncertain.

What the written plan should actually contain

A useful plan answers practical questions rather than restating the diagnosis. The exact content depends on your cancer, the specific immunotherapy, and how you responded, so treat the following as a checklist to discuss with the treating team, not a universal template.

First, identification. The plan should name the treating clinician or department, the hospital, and a contact route for non-urgent questions. It should also name the person responsible for reviewing results after you leave.

Second, the treatment record. The plan should state the specific agent or regimen, the dates and number of cycles given, the last dose date, and whether treatment is complete, paused, or intended to continue elsewhere. If continuation is intended, the plan should say what the receiving clinician needs to confirm before the next dose.

Third, monitoring. The plan should list which tests are wanted, at what intervals, and what each test is looking for. It should distinguish tests that must be done at a specific facility from tests any qualified laboratory can run.

Fourth, results flow. The plan should state how results are sent, to whom, and in what timeframe. Ask whether the Chinese team wants to review results before your home clinician acts, or whether the home clinician has authority to manage independently.

Fifth, escalation. The plan should say what findings should prompt contact with the Chinese team, what findings need urgent local care, and what to do outside working hours. Ask the team to write this part in plain terms rather than general reassurance, because it is the section that matters when something unexpected appears and the people who wrote the plan are no longer in the room.

Sixth, responsibility. For each item, the plan should name who is responsible: the Chinese clinician, your home clinician, or you. If responsibility is shared, the plan should say who decides when the two teams disagree.

Records to request before you leave

The written plan is only useful if it travels with the records that support it. Request copies of the key documents while you are still on site, when staff can locate and release them.

Ask for the pathology report, imaging reports and the actual images if available, biomarker and genomic test results, treatment records with dates and doses, and the most recent laboratory results. Ask whether the hospital can provide these in English or with a certified translation, and whether there is a fee or a processing time for copies.

Keep the records yourself rather than relying on the hospital to send them later. A patient-held copy means your home clinician can start reviewing without waiting for an international records request.

One practical point: ask the treating team to mark which documents are essential for the receiving clinician and which are background. A complete archive is not always more useful than a focused set.

• Pathology and biomarker reports, with the date and laboratory name.
• Imaging reports and, where possible, the images themselves.
• Treatment record: agent, dose, cycle dates, last dose, and any dose changes.
• Most recent laboratory and assessment results.
• The written follow-up plan itself, signed or clearly attributed to a named clinician.

Contact routes and what each one is for

Overseas patients often leave with a single phone number and no clarity about when to use it. Ask the team to separate contact routes by purpose.

There is a difference between a scheduling question, a clinical question about a result, and an urgent concern. The plan should say which route to use for each, and what response to expect. Ask whether the team uses email, a patient portal, or a messaging application, and whether clinical questions are answered through that channel.

Ask who monitors the channel and during what hours. If the answer is that no one monitors it outside working hours, the plan should say what to do instead, which usually means contacting local emergency care.

Language matters here. If you do not speak Chinese, ask whether the contact route supports English, and whether interpretation is available for clinical discussions. Do not assume that a general enquiry line can handle a clinical question.

Finally, ask for the plan to state what information you should include when you make contact: your name, the dates of treatment, the specific question, and the relevant result. A structured message gets a faster and more useful reply.

Who is responsible for what after you go home

A frequent gap in cross-border follow-up is not missing records but unclear responsibility. Two clinicians can each assume the other is acting, and the patient is left to notice the omission. That is why the plan should read less like a summary of care and more like a list of named owners.

The written plan should assign each monitoring task to a named party. If the Chinese team wants to review a scan before any change, that should be stated. If the home clinician is expected to manage independently and only inform the Chinese team, that should be stated too.

Ask what happens if the two teams disagree about the next step. A plan that does not address this leaves you in the middle of a clinical disagreement you are not equipped to resolve.

Ask also who is responsible for acting on an abnormal result. Receiving a result and acting on it are different tasks. The plan should make clear which one the Chinese team is taking on.

If you are considering returning to China for further treatment, the plan should say what would need to be reassessed and what records would be required. This is a question to confirm with the treating team, not an assumption that return is possible or appropriate.

Questions to ask before you sign off on the plan

Treat the written plan as a document you review, not one you simply receive. Read it before discharge and ask for clarification while the treating team is still available.

Ask whether the plan reflects the final assessment or a provisional one. If further tests are pending, the plan should say so and state when it will be updated.

Ask whether the plan is specific to your cancer type and treatment, or a general template. A plan that does not name your agent, your monitoring tests, and your contact clinician is not yet complete.

Ask what could change the plan. If a scan result, a laboratory value, or a change in your condition would alter the monitoring schedule, the plan should describe that trigger.

Ask for the plan in a format you can share. A scanned signed copy and a plain text version are both useful; a photograph of a handwritten note is not.

Finally, confirm that the plan includes the name and contact details of the clinician who will review your results, and that this person knows you are leaving China. A plan that names someone who has not been informed is not yet operational.

If you want help organising the records and the questions before your appointment, ChinaSpecialistCare can review a brief summary and suggest the relevant next step. An initial enquiry is free and does not commit you to any service. The treating hospital decides suitability, and no review establishes that a specific immunotherapy is appropriate or available for your diagnosis.

Related treatment reference